{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:16:07Z","timestamp":1788200167575,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A hypercoagulable condition is typical of patients with acute coronary syndrome and is a determining factor in the genesis of recurrent ischaemic events. Modern pharmacological therapies consisting of antiplatelets and anticoagulants derive their rationale for use on the pathophysiological mechanisms most commonly associated with myocardial infarction (MI); they have contributed to reducing the ischaemic risk of these patients, but left ample room for improvement. In particular, trials that have studied the association of an anticoagulant with antiplatelet drugs have provided promising results in terms of efficacy, but highlighted a significant bleeding risk. Evidence derived from experimental animal and epidemiological studies has shown how factor XI (FXI) deficiency is associated with a reduction in thrombotic events but with modest bleeding. These data added to the role that FXI plays in the coagulation cascade constituted an incipit for the pharmacological attempt to decouple thrombosis from haemostasis by means of the inhibition of this factor. The theoretical assumption that FXI inhibitor drugs may be able to reduce the ischaemic risk without significantly increasing the haemorrhagic risk makes these compounds a potential therapeutic aid for patients in secondary prevention after acute MI. To date, on these patients, we only have data from a Phase 2 trial, PACIFIC-AMI (Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2 433 334 in Patients Following an Acute Heart Attack). In this study, the primary endpoint\u2014represented by the Bleeding Academic Research Consortium (BARC) composite of Type 2, 3, or 5 bleeding\u2014showed no significant differences between the various doses of asundexian tested (10, 20, and 50 mg quoque die), and between these and placebo (asundexian all doses vs. placebo: hazard ratio, 0.98; 90% confidence interval, 0.71\u20131.35). The data on efficacy, however, showed neutral results, but it should be noted that the study did not have the adequate statistical power to evaluate this outcome. Valuable information could, therefore, derive in the future from the ongoing Phase 3 trial with milvexian, LIBREXIA-ACS (A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome) and from any future studies that could be started by testing different molecules.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae013","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:43:29Z","timestamp":1713354209000},"page":"i29-i34","source":"Crossref","is-referenced-by-count":11,"title":["Factor XI inhibition in patients with acute coronary syndrome"],"prefix":"10.1093","volume":"26","author":[{"given":"Carmelo","family":"Raffo","sequence":"first","affiliation":[{"name":"Cardiovascular Department, A.O.U. Polyclinic \u2018G. Rodolico\u2014San Marco\u2019, University of Catania , Catania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, A.O.U. Polyclinic \u2018G. Rodolico\u2014San Marco\u2019, University of Catania , Catania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2024041706401299600_suae013-B1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2991\/jegh.k.201217.001","article-title":"Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review","volume":"11","author":"Ralapanawa","year":"2021","journal-title":"J Epidemiol Glob Health"},{"key":"2024041706401299600_suae013-B2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jama.2022.0358","article-title":"Diagnosis and treatment of acute coronary syndromes: a review","volume":"327","author":"Bhatt","year":"2022","journal-title":"JAMA"},{"key":"2024041706401299600_suae013-B3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCRESAHA.118.311098","article-title":"Reassessing the mechanisms of acute coronary syndromes","volume":"124","author":"Libby","year":"2019","journal-title":"Circ Res"},{"key":"2024041706401299600_suae013-B4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"2024041706401299600_suae013-B5","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"2024041706401299600_suae013-B6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/2040620717733691","article-title":"The role of oral anticoagulant therapy in patients with acute coronary syndrome","volume":"8","author":"Moon","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"2024041706401299600_suae013-B7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clinthera.2023.09.027","article-title":"Safety and efficacy of direct oral anticoagulant in addition to antiplatelet therapy after acute coronary syndrome: a systemic review and meta-analysis of 53,869 patients","volume":"46","author":"Alharbi","year":"2024","journal-title":"Clin Ther"},{"key":"2024041706401299600_suae013-B8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"2024041706401299600_suae013-B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2024041706401299600_suae013-B10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11239-023-02821-x","article-title":"Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease","volume":"56","author":"Mazzone","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2024041706401299600_suae013-B11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamacardio.2017.5306","article-title":"Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: a systematic review and meta-analysis","volume":"3","author":"Chiarito","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2024041706401299600_suae013-B12","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2024041706401299600_suae013-B13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2019","journal-title":"Eur Heart J"},{"key":"2024041706401299600_suae013-B14","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","article-title":"Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy","volume":"42","author":"Aboyans","year":"2021","journal-title":"Eur Heart J"},{"key":"2024041706401299600_suae013-B15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"key":"2024041706401299600_suae013-B16","first-page":"437","article-title":"Factor XI\/XIa inhibition: the arsenal in development for a new therapeutic target in cardio- and cerebrovascular disease","volume":"9","author":"Badimon","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"2024041706401299600_suae013-B17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"2024041706401299600_suae013-B18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur Heart J"},{"key":"2024041706401299600_suae013-B19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024041706401299600_suae013-B20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_1\/i29\/57239804\/suae013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_1\/i29\/57239804\/suae013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:43:40Z","timestamp":1713354220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/26\/Supplement_1\/i29\/7646234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":20,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae013","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4]]}}}